Kevin C. Oboyle
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
CARL CFO Appointment and FY2026 Revenue Guidance Confirmed. Carlsmed announced Richard Heppenstall as its new chief financial officer, succeeding Leo Greenstein. The company also reaffirmed its FY2026 sales guidance of $74 million to $78 million, matching analyst estimates. BTIG kept its price target at $23 following the announcements.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
iRhythm Reports Data Breach and Completes VitalConnect Acquisition. iRhythm disclosed unauthorized access to patient data, a significant security event for a healthcare company. The firm also completed the acquisition of VitalConnect to expand its cardiac monitoring platform across various care settings. Analyst views remain mixed, with Wells Fargo lowering its price target to $150 while Needham raised its target to $194.
Transaction History
| OM | ▲ Buy | Grant | 10,667 | $0 | 6/4/2026 | View on chart |
| CARL | ▲ Buy | Grant | 13,698 | $0 | 6/3/2026 | View on chart |
| IRTC | ▲ Buy | Grant | 1,573 | $0 | 5/27/2026 | View on chart |
| CARL | ▲ Buy | Grant | 17,333 | $0 | 7/22/2025 | View on chart |
| IRTC | ▲ Buy | Grant | 2,035 | $0 | 7/7/2025 | View on chart |
| OM | ▲ Buy | Grant | 8,983 | $0 | 6/2/2025 | View on chart |
| OM | ▲ Buy | Grant | 15,135 | $0 | 5/14/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Hims & Hers news mentioned in broader market context
Recent coverage from Yahoo discusses reasons to retain Hims & Hers stock, which shares the digital health sector with Outset Medical. While the article focuses on a different company, it highlights ongoing investor interest in the broader telehealth and digital medicine space. Outset Medical remains a high-beta stock with significant volatility, as seen in its wide 52-week range.
Hims & Hers news mentioned in broader market context. Recent coverage from Yahoo discusses reasons to retain Hims & Hers stock, which shares the digital health sector with Outset Medical. While the article focuses on a different company, it highlights ongoing investor interest in the broader telehealth and digital medicine space. Outset Medical remains a high-beta stock with significant volatility, as seen in its wide 52-week range.